MedImmune: Open, transparent and collaborative




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: MedImmune: Open, transparent and collaborative
Released on: July 11, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Jane Osbourne (Vice President, Research and Development at MedImmune), discusses AstraZeneca’s recent move to Cambridge, the company’s strategy for collaboration.
  • Summary
  • Transcript
  • Participants
  • Company
Jane Osbourne (Vice President, Research and Development at MedImmune), discusses AstraZeneca’s recent move to Cambridge, the company’s strategy for collaboration. She also discusses her role with BIA, changes to the industry funding model, and the implications of ‘Brexit’.
Jane Osbourne (Vice President, Research and Development at MedImmune), discusses AstraZeneca’s recent move to Cambridge, the company’s strategy for collaboration. She also discusses her role with BIA, changes to the industry funding model, and the implications of ‘Brexit’.
Jane joined MedImmune, formerly Cambridge Antibody Technology (CAT), in September 1993. Through a number of increasingly senior roles she originated several key publications and patents, and also made a significant contribution to the discovery and development of marketed drugs and more than 40 clinical candidates. Prior to joining CAT, Jane obtained a First Class degree in Natural Sciences (Biochemistry) from the University of Cambridge and completed a PhD at the John Innes Centre for Plant Science Research in Norwich. This was followed by a post doctoral position at Rutgers University, New Jersey before moving into medical research through a British Heart Foundation Post Doctoral Fellowship at the Department of Medicine at Addenbrooke's Hospital in Cambridge. In 2010 Jane won the Institute of Directors’ East of England Business Woman of the Year Award in recognition of her contribution to the successful integration and development of CAT and MedImmune in Cambridge. Jane is a member of the Board of the BioIndustry Association, a member of the Board of Babraham Bioscience Technologies and a member of the UK Medical Research Council Industry Grant Award Assessment Panel. She is an editor of both ‘Mab Journal’ and ‘Protein Engineering Design and Selection’.
Medimmune
In the world of biologics, MedImmune has established itself as a true visionary, with one of the most robust pipelines in the biopharmaceutical industry. From groundbreaking research and development, to state-of-the-art manufacturing, to product commercialization, every day we're touching lives. We're proudly united by the spirit of innovation, the heart of inspiration, and the strength of integration, as we advance science for better health.